Sculptor Capital’s Viking Therapeutics VKTX Stock Holding History

Sculptor Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-173,500	Closed	-$1.39M	–	303
2019 Q4	$1.39M	Hold	173,500	–	–	0.01%	193
2019 Q3	$1.19M	Sell	173,500 -262,100	-60%	-$1.95M	0.01%	222
2019 Q2	$3.62M	Hold	435,600	–	–	0.02%	143
2019 Q1	$4.33M	Buy	+435,600	New	+$3.65M	0.03%	107

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Sculptor Capital's VKTX Position: Q1 2020 in Review

Sculptor Capital sold out of Viking Therapeutics (VKTX) in Q1 2020, closing a stake of 173,500 shares — an estimated $1.39M sold.

Sculptor Capital first reported a position in VKTX in Q1 2019 and held it in 4 quarters. The position peaked at $4.33M in Q1 2019. 137 funds tracked by Wall St. Rank hold VKTX as of Q1 2020.

Sculptor Capital reported no remaining Viking Therapeutics position as of Q1 2020 after selling out during the quarter.
Sculptor Capital sold 173,500 Viking Therapeutics shares in Q1 2020, an estimated $1.39M.
Sculptor Capital first reported a position in Viking Therapeutics in Q1 2019 and held it in 4 quarters.
Sculptor Capital's Viking Therapeutics position peaked at $4.33M in Q1 2019.
137 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2020.

Based on Sculptor Capital's 13F filing for Q1 2020, filed 14 May 2020.